Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | HLA-DRB1 | P01911 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344706 | 0.88 | KDM1A (0.40) | CD274PDCD1LG2MEN1ALDH1A1KMT2A | |
| SCHEMBL1346292 | 0.88 | KDM1A (0.39) | VEGFAEGLN1CD274PDCD1LG2SCN9A | |
| SCHEMBL1346884 | 0.87 | NPC1 (0.40) | VEGFAEGLN1CD274PDCD1LG2SCN9A | |
| SCHEMBL1344710 | 0.84 | VEGFA (0.38) | VEGFAEGLN1CD274PDCD1LG2MEN1 | |
| SCHEMBL1346502 | 0.84 | KMT2A (0.40) | CD274PDCD1LG2MEN1ALDH1A1KMT2A | |
| SCHEMBL1346140 | 0.82 | VEGFA (0.36) | VEGFAEGLN1CD274PDCD1LG2SCN9A | |
| SCHEMBL1346177 | 0.81 | MAPT (0.36) | VEGFAEGLN1CD274PDCD1LG2SCN9A | |
| SCHEMBL1347282 | 0.81 | KDM1A (0.40) | VEGFAEGLN1CD274PDCD1LG2SCN9A | |
| SCHEMBL1346314 | 0.81 | KDM4E (0.45) | CD274PDCD1LG2MEN1ALDH1A1KMT2A | |
| SCHEMBL1347183 | 0.81 | MEN1 (0.43) | VEGFAEGLN1CD274PDCD1LG2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063039-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-11-22 | — | — | US | claimed |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A., (IT) | 2010-02-25 | — | — | US | claimed |
| EP-1685103-B1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARM SPA (IT) | 2008-07-30 | — | — | EP | claimed |
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | claimed |
| JP-2007511564-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1685103-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-02 | — | — | EP | claimed |
| WO-2005054190-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | claimed |
| EP-1533298-A1 | 3-aminopyrrolidone derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | claimed |
| US-8063039-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-11-22 | — | — | US | disclosed |
| US-7968592-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A., (IT) | 2010-02-25 | — | — | US | disclosed |
| EP-1685103-B1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARM SPA (IT) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | disclosed |
| EP-1685103-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005054190-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | disclosed |
| EP-1533298-A1 | 3-aminopyrrolidone derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | TRPC3, TRPV3, CACNA1D | VEGFA 4537/4885EGLN1 3688/4885CD274 3979/4885 |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | TRPC3, TRPV3, CACNA1D | VEGFA 4537/4885EGLN1 3688/4885CD274 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.